Logo image of ADVM

ADVERUM BIOTECHNOLOGIES INC (ADVM) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ADVM - US00773U2078 - Common Stock

4.36 USD
+0.1 (+2.35%)
Last: 12/8/2025, 8:00:00 PM
4.6 USD
+0.24 (+5.5%)
After Hours: 12/8/2025, 8:00:00 PM
Fundamental Rating

1

ADVM gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 530 industry peers in the Biotechnology industry. ADVM may be in some trouble as it scores bad on both profitability and health. ADVM is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ADVM had negative earnings in the past year.
In the past year ADVM has reported a negative cash flow from operations.
ADVM had negative earnings in each of the past 5 years.
ADVM had a negative operating cash flow in each of the past 5 years.
ADVM Yearly Net Income VS EBIT VS OCF VS FCFADVM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

The Return On Assets of ADVM (-180.84%) is worse than 88.72% of its industry peers.
Industry RankSector Rank
ROA -180.84%
ROE N/A
ROIC N/A
ROA(3y)-63.55%
ROA(5y)-49.62%
ROE(3y)-136.88%
ROE(5y)-96.75%
ROIC(3y)N/A
ROIC(5y)N/A
ADVM Yearly ROA, ROE, ROICADVM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ADVM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ADVM Yearly Profit, Operating, Gross MarginsADVM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K -20K -25K

More info and screens

0

2. Health

2.1 Basic Checks

ADVM does not have a ROIC to compare to the WACC, probably because it is not profitable.
ADVM has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, ADVM has more shares outstanding
There is no outstanding debt for ADVM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ADVM Yearly Shares OutstandingADVM Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
ADVM Yearly Total Debt VS Total AssetsADVM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

Based on the Altman-Z score of -29.55, we must say that ADVM is in the distress zone and has some risk of bankruptcy.
ADVM has a Altman-Z score of -29.55. This is amonst the worse of the industry: ADVM underperforms 88.53% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -29.55
ROIC/WACCN/A
WACC8.8%
ADVM Yearly LT Debt VS Equity VS FCFADVM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M 400M

2.3 Liquidity

ADVM has a Current Ratio of 0.65. This is a bad value and indicates that ADVM is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.65, ADVM is not doing good in the industry: 90.79% of the companies in the same industry are doing better.
ADVM has a Quick Ratio of 0.65. This is a bad value and indicates that ADVM is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.65, ADVM is doing worse than 90.23% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.65
Quick Ratio 0.65
ADVM Yearly Current Assets VS Current LiabilitesADVM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for ADVM have decreased strongly by -43.24% in the last year.
The Revenue for ADVM has decreased by -72.22% in the past year. This is quite bad
The Revenue has been growing by 31.95% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-43.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-56.15%
Revenue 1Y (TTM)-72.22%
Revenue growth 3Y-48.91%
Revenue growth 5Y31.95%
Sales Q2Q%-100%

3.2 Future

The Earnings Per Share is expected to grow by 3.72% on average over the next years.
ADVM is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 75.61% yearly.
EPS Next Y-17.8%
EPS Next 2Y16.23%
EPS Next 3Y13.13%
EPS Next 5Y3.72%
Revenue Next Year1166.67%
Revenue Next 2Y-50%
Revenue Next 3Y-34.14%
Revenue Next 5Y75.61%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ADVM Yearly Revenue VS EstimatesADVM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2023 2024 2025 2026 2027 2029 2030 2031 2032 50M 100M 150M 200M
ADVM Yearly EPS VS EstimatesADVM Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -10 -20 -30

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ADVM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ADVM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ADVM Price Earnings VS Forward Price EarningsADVM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ADVM Per share dataADVM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6 -8

4.3 Compensation for Growth

A more expensive valuation may be justified as ADVM's earnings are expected to grow with 13.13% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.23%
EPS Next 3Y13.13%

More info and screens

0

5. Dividend

5.1 Amount

ADVM does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

ADVERUM BIOTECHNOLOGIES INC

NASDAQ:ADVM (12/8/2025, 8:00:00 PM)

After market: 4.6 +0.24 (+5.5%)

4.36

+0.1 (+2.35%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2025-11-12/amc
Earnings (Next)03-16 2026-03-16/amc
Inst Owners52.99%
Inst Owner Change0.32%
Ins Owners11.52%
Ins Owner Change-114.5%
Market Cap96.27M
Revenue(TTM)1.00M
Net Income(TTM)-130.93M
Analysts76.67
Price Target5 (14.68%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-14.1%
Min EPS beat(2)-26.1%
Max EPS beat(2)-2.11%
EPS beat(4)0
Avg EPS beat(4)-22.8%
Min EPS beat(4)-41.41%
Max EPS beat(4)-2.11%
EPS beat(8)3
Avg EPS beat(8)-2.48%
EPS beat(12)6
Avg EPS beat(12)0.59%
EPS beat(16)7
Avg EPS beat(16)-3.35%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-56.25%
PT rev (3m)-74.87%
EPS NQ rev (1m)-68.81%
EPS NQ rev (3m)-138.96%
EPS NY rev (1m)-11.22%
EPS NY rev (3m)-24.05%
Revenue NQ rev (1m)-97.37%
Revenue NQ rev (3m)-98.24%
Revenue NY rev (1m)0.07%
Revenue NY rev (3m)-33.29%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 96.27
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-8.58
EYN/A
EPS(NY)-3.67
Fwd EYN/A
FCF(TTM)-6.27
FCFYN/A
OCF(TTM)-6.25
OCFYN/A
SpS0.05
BVpS-2.52
TBVpS-2.52
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -180.84%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-63.55%
ROA(5y)-49.62%
ROE(3y)-136.88%
ROE(5y)-96.75%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 21.78%
Cap/Sales 54.3%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.65
Quick Ratio 0.65
Altman-Z -29.55
F-Score2
WACC8.8%
ROIC/WACCN/A
Cap/Depr(3y)68.65%
Cap/Depr(5y)163.27%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-43.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-56.15%
EPS Next Y-17.8%
EPS Next 2Y16.23%
EPS Next 3Y13.13%
EPS Next 5Y3.72%
Revenue 1Y (TTM)-72.22%
Revenue growth 3Y-48.91%
Revenue growth 5Y31.95%
Sales Q2Q%-100%
Revenue Next Year1166.67%
Revenue Next 2Y-50%
Revenue Next 3Y-34.14%
Revenue Next 5Y75.61%
EBIT growth 1Y-12.41%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-85.18%
EBIT Next 3Y-34.82%
EBIT Next 5Y-28.82%
FCF growth 1Y-55.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-56.62%
OCF growth 3YN/A
OCF growth 5YN/A

ADVERUM BIOTECHNOLOGIES INC / ADVM FAQ

What is the fundamental rating for ADVM stock?

ChartMill assigns a fundamental rating of 1 / 10 to ADVM.


Can you provide the valuation status for ADVERUM BIOTECHNOLOGIES INC?

ChartMill assigns a valuation rating of 0 / 10 to ADVERUM BIOTECHNOLOGIES INC (ADVM). This can be considered as Overvalued.


What is the profitability of ADVM stock?

ADVERUM BIOTECHNOLOGIES INC (ADVM) has a profitability rating of 0 / 10.


Can you provide the financial health for ADVM stock?

The financial health rating of ADVERUM BIOTECHNOLOGIES INC (ADVM) is 0 / 10.


Can you provide the expected EPS growth for ADVM stock?

The Earnings per Share (EPS) of ADVERUM BIOTECHNOLOGIES INC (ADVM) is expected to decline by -17.8% in the next year.